Overview

A Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced Participants With Active Psoriatic Arthritis

Status:
RECRUITING
Trial end date:
2028-10-18
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy of icotrokinra compared to placebo in biologic-experienced participants with active psoriatic arthritis (PsA) by assessing the reduction in signs and symptoms of PsA.
Phase:
PHASE3
Details
Lead Sponsor:
Janssen Research & Development, LLC